Action
What to keep, what to improve
Consumer AI answers. For each outcome, the sources that currently support it and the sources where representation could be improved. Language stays pharma-safe: we improve scientific representation and information accessibility — never attempt to manipulate AI.
Mention
Wegovy appears in two thirds of relevant answers, mostly through general-web and trial sources.
STEP trials / PubMed
Consistently present wherever Wegovy is named.
Turkish Endocrinology Society
Strong local anchor for brand mentions.
Wikipedia / general web
Carries the mention but with dated framing.
Hospital websites (TR)
Frequently cited, rarely name the brand.
Recommendation
When mentioned, Wegovy is recommended in about half of answers; guideline sources travel with recommendations.
ADA Standards of Care
Appears alongside most recommendation answers.
SURMOUNT / SURPASS
Comparative trial context supports the recommendation.
Turkish obesity guidelines
Rarely surfaced in Turkish-language answers.
Turkish Ministry of Health
Under-represented for a reimbursement-heavy market.
#1 Recommendation
First-position recommendations are led by comparative trial evidence.
STEP trials / PubMed
Most frequent source behind first-position answers.
SURMOUNT / SURPASS
Currently appears more often alongside the competitor.
ADA Standards of Care
Cited, but without brand-specific detail.
Top 3 Recommendation
Top-3 presence is stable and driven by society and guideline sources.
Turkish Endocrinology Society
Reliable driver of top-3 presence locally.
ADA Standards of Care
Global guideline backing for the shortlist.
Hospital websites (TR)
Present in answers, but list surgery ahead of pharmacotherapy.
Strongest Attribute
Convenience is the strongest attribute in both audiences.
FDA label / Turkish label
Dosing schedule is reproduced accurately.
STEP trials / PubMed
Supports the once-weekly narrative.
Social media / forums
Convenience framing is inconsistent in consumer answers.
Weakest Attribute
Access and availability is the weakest attribute in both audiences.
Turkish Ministry of Health
The one authoritative access source currently appearing.
Turkish obesity guidelines
Little clarity on where pharmacotherapy sits locally.
Hospital websites (TR)
Access information is fragmented and often out of date.
Social media / forums
Fills the reimbursement gap with unverified claims.